Suppr超能文献

转移性肺病变作为肿瘤浸润淋巴细胞免疫治疗的首选切除部位。

Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.

作者信息

Ben-Avi Ronny, Itzhaki Orit, Simansky David, Zippel Dov, Markel Gal, Ben Nun Alon, Schachter Jacob, Besser Michal J

机构信息

Departments of *Thoracic Surgery †Ella Lemelbaum Institute of Melanoma ‡General and Bariatric Surgery, Sheba Medical Center, Tel Hashomer §Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

J Immunother. 2016 Jun;39(5):218-22. doi: 10.1097/CJI.0000000000000124.

Abstract

Adoptive cell therapy with tumor infiltrating lymphocytes (TIL) yields 50% response rates in metastatic melanoma and shows promising clinical results in other solid tumors. Autologous TIL cultures are isolated from resected tumor tissue, expanded ex vivo to large numbers and reinfused to the preconditioned patient. In this prospective study, we validate the origin of the tumor biopsy and its effect on T-cell function and clinical response. One hundred forty-four patients underwent surgery and 79 patients were treated with TIL adoptive cell therapy. Cultures from lung tissue were compared with other origins. The success rate of establishing TIL culture from lung tissue was significantly higher compared with nonlung tissue (94% vs. 72%, respectively, P≤0.003). Lung-derived TIL cultures gave rise to higher cell numbers (P≤0.011) and exhibited increased in vitro antitumor reactivity. The average fold expansion for lung-derived TIL during a rapid expansion procedure was 1349±557 compared with 1061±473 for nonlung TIL (P≤0.038). Patients treated with TIL cultures of lung origin (compared with nonlung) had prolonged median overall survival (29 vs. 9.5 mo; P≤0.065). Given the remarkable advancement in minimally invasive thoracic surgery and the results of this study, we suggest efforts should be taken to resect lung metastasis rather than other sites to generate TIL cultures for clinical use.

摘要

采用肿瘤浸润淋巴细胞(TIL)进行过继性细胞治疗在转移性黑色素瘤中产生了50%的缓解率,并且在其他实体瘤中显示出有前景的临床结果。自体TIL培养物从切除的肿瘤组织中分离出来,在体外大量扩增后再回输到经过预处理的患者体内。在这项前瞻性研究中,我们验证了肿瘤活检的来源及其对T细胞功能和临床反应的影响。144例患者接受了手术,79例患者接受了TIL过继性细胞治疗。将来自肺组织的培养物与其他来源的培养物进行比较。与非肺组织相比,从肺组织建立TIL培养物的成功率显著更高(分别为94%和72%,P≤0.003)。源自肺的TIL培养物产生了更高的细胞数量(P≤0.011),并且表现出增强的体外抗肿瘤反应性。在快速扩增过程中,源自肺的TIL的平均扩增倍数为1349±557,而非肺TIL为1061±473(P≤0.038)。接受源自肺的TIL培养物治疗的患者(与非肺来源相比)的中位总生存期延长(29个月对9.5个月;P≤0.065)。鉴于微创胸外科手术的显著进展以及本研究的结果,我们建议应努力切除肺转移灶而非其他部位以产生用于临床的TIL培养物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验